Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SV-102 after cryolysis in advanced/metastatic prostate cancer
NCT05544227Phase 1Completed
- Sponsor
- Williams Cancer Foundation
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Device-based Delivery, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SYNC-T in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Williams Cancer Foundation. Primary endpoint: Treatment-related adverse events at 30 days. Started Feb 2023; status: completed.
02
Drugs
SYNC-T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05544227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05544227.